Title |
Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review
|
---|---|
Published in |
International Journal of Clinical Oncology, February 2017
|
DOI | 10.1007/s10147-017-1104-3 |
Pubmed ID | |
Authors |
Juntaro Matsuzaki, Takahiro Ochiya |
Abstract |
Circulating non-coding RNAs, including microRNAs and long non-coding RNAs, and the protein components of extracellular vesicles are promising biomarkers for the non-invasive detection of cancer at an early stage. This systematic review discusses the increasing number of well-designed cancer biomarker-related studies that have been published worldwide. In many of these studies, high diagnostic accuracy, which is represented as the area under the receiver operating characteristic curve being >0.8, could be achieved using combinations of circulating microRNAs. In addition, similar diagnostic accuracies were reported using long non-coding RNAs or proteins present in extracellular vesicles, although these evidences were based on a limited number of studies. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Korea, Republic of | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | <1% |
Switzerland | 1 | <1% |
Austria | 1 | <1% |
Unknown | 131 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 30 | 22% |
Student > Ph. D. Student | 29 | 22% |
Student > Master | 13 | 10% |
Student > Bachelor | 10 | 7% |
Student > Doctoral Student | 7 | 5% |
Other | 16 | 12% |
Unknown | 29 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 42 | 31% |
Medicine and Dentistry | 25 | 19% |
Agricultural and Biological Sciences | 9 | 7% |
Computer Science | 4 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
Other | 16 | 12% |
Unknown | 34 | 25% |